Perspective Therapeutics Inc. (CATX) - Total Liabilities
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has total liabilities worth $63.33 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CATX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Perspective Therapeutics Inc. - Total Liabilities Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Perspective Therapeutics Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Perspective Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Perspective Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
USA | $27.18 Million |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
Thailand | ฿10.45 Billion |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥420.92 Million |
|
Daodaoquan Grain and Oil Co Ltd
SHE:002852
|
China | CN¥2.19 Billion |
|
Kaiser China Holding Co Ltd
SHE:002425
|
China | CN¥419.04 Million |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
China | CN¥191.82 Million |
|
Wuhan DDMC Culture Co Ltd
SHG:600136
|
China | CN¥601.46 Million |
|
Binh Minh Plastics JSC
VN:BMP
|
Vietnam | ₫503.34 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Perspective Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Perspective Therapeutics Inc. asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Perspective Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual total liabilities of Perspective Therapeutics Inc. from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $59.94 Million | +18.85% |
| 2024-12-31 | $50.43 Million | +122.05% |
| 2023-12-31 | $22.71 Million | +558.51% |
| 2023-06-30 | $3.45 Million | 0.00% |
| 2022-12-31 | $3.45 Million | +9.08% |
| 2022-06-30 | $3.16 Million | 0.00% |
| 2021-12-31 | $3.16 Million | +5.05% |
| 2021-06-30 | $3.01 Million | +9.85% |
| 2020-12-31 | $2.74 Million | -7.93% |
| 2020-06-30 | $2.98 Million | 0.00% |
| 2019-12-31 | $2.98 Million | +70.84% |
| 2019-06-30 | $1.74 Million | 0.00% |
| 2018-12-31 | $1.74 Million | -28.16% |
| 2018-06-30 | $2.42 Million | +45.47% |
| 2017-12-31 | $1.67 Million | 0.00% |
| 2017-06-30 | $1.67 Million | -1.99% |
| 2016-12-31 | $1.70 Million | 0.00% |
| 2016-06-30 | $1.70 Million | -23.42% |
| 2015-12-31 | $2.22 Million | 0.00% |
| 2015-06-30 | $2.22 Million | -14.36% |
| 2014-12-31 | $2.59 Million | 0.00% |
| 2014-06-30 | $2.59 Million | +53.54% |
| 2013-12-31 | $1.69 Million | 0.00% |
| 2013-06-30 | $1.69 Million | +0.11% |
| 2012-12-31 | $1.69 Million | 0.00% |
| 2012-06-30 | $1.69 Million | +17.47% |
| 2011-12-31 | $1.44 Million | 0.00% |
| 2011-06-30 | $1.44 Million | -17.78% |
| 2010-12-31 | $1.75 Million | 0.00% |
| 2010-06-30 | $1.75 Million | -1.78% |
| 2009-12-31 | $1.78 Million | 0.00% |
| 2009-06-30 | $1.78 Million | -12.69% |
| 2008-12-31 | $2.04 Million | 0.00% |
| 2008-06-30 | $2.04 Million | -39.37% |
| 2007-12-31 | $3.36 Million | 0.00% |
| 2007-06-30 | $3.36 Million | +21.29% |
| 2006-12-31 | $2.77 Million | 0.00% |
| 2006-06-30 | $2.77 Million | -87.03% |
| 2005-06-30 | $21.36 Million | 0.00% |
| 2004-12-31 | $21.36 Million | +3678.79% |
| 2004-06-30 | $565.13K | -47.86% |
| 2003-12-31 | $1.08 Million | 0.00% |
| 2003-06-30 | $1.08 Million | +4.89% |
| 2002-12-31 | $1.03 Million | 0.00% |
| 2002-06-30 | $1.03 Million | -19.47% |
| 2001-12-31 | $1.28 Million | +4.75% |
| 2000-12-31 | $1.23 Million | -4.54% |
| 2000-06-30 | $1.28 Million | -61.23% |
| 1999-12-31 | $3.31 Million | +170.16% |
| 1999-06-30 | $1.23 Million | -63.79% |
| 1998-12-31 | $3.38 Million | +2.23% |
| 1998-06-30 | $3.31 Million | -9.17% |
| 1997-12-31 | $3.64 Million | +7.69% |
| 1997-06-30 | $3.38 Million | +29.78% |
| 1996-12-31 | $2.61 Million | -28.45% |
| 1996-06-30 | $3.64 Million | +41.17% |
| 1995-12-31 | $2.58 Million | -1.00% |
| 1995-06-30 | $2.61 Million | +1.01% |
| 1994-12-31 | $2.58 Million | 0.00% |
| 1994-06-30 | $2.58 Million | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more